Meet Ernest Hawk, M.D.
Ernest Hawk, M.D., M.P.H.
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
About Dr. Hawk
Ernest Hawk, M.D., MPH, is vice president and head of the division of Cancer Prevention and Population Sciences at The University of Texas MD Anderson Cancer Center and holds the T. Boone Pickens Distinguished Chair for Early Prevention of Cancer. Additional responsibilities include leadership of the Duncan Family Institute for Cancer Prevention and Risk Assessment and co-leadership of MD Anderson’s Cancer Prevention and Control Platform which advances community health promotion and cancer control through evidence-based public policy, public and professional education, and community-based service implementation and dissemination.A native of Detroit, Michigan, Dr. Hawk earned his medical degree from Wayne State University and his Master of Public Health degree at Johns Hopkins University. He completed an internal medicine internship and residency at Emory University, a medical oncology clinical fellowship at the University of California, San Francisco, and a cancer prevention fellowship at the National Cancer Institute (NCI).Prior to his appointment at MD Anderson in December 2007, Dr. Hawk held several positions at the NCI in Bethesda, MD. He most recently served as director of the Office of Centers, Training and Resources, responsible for the NCI’s cancer centers program, a major translational science program (i.e., the SPORE program), the NCI’s extramural training enterprise, and its extramural disparities portfolio. His prior NCI posts included chief and medical officer of the Gastrointestinal and Other Cancers Research Group, medical officer in the Chemoprevention Branch, and chair of the Translational Research Working Group.Dr. Hawk has been involved in a wide range of preclinical and clinical chemoprevention research, including developmental studies of nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, and preventive agent combinations in high-risk cohorts. Interests include the improvement of minority and medically underserved populations’ participation in clinical research, future applications of multi-cancer early detection tests, and the integration of risk assessment, behavioral science, and preventive strategies developed through sequential clinical trials for application in clinical or public health settings. He has published more than 180 scientific articles and book chapters, edited three books, serves as an editor of Holland & Frei’s Cancer Medicine (10th edition), and serves as the senior deputy editor for Cancer Prevention Research, and on the editorial board of Cancer Medicine.Dr. Hawk can be reached at 713-792-3900 or through his Office Manager, Wendy McDaniel at 713-745-0490 or via email (wcmcdaniel@mdanderson.org)
Read More
Present Title & Affiliation
Primary Appointment
Co-Director, Department of CCSG, Community Outreach and Engagement Component, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Boone Pickens Distinguished Chair for Early Prevention of Cancer, Department of Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Director, Duncan Family Institute for Cancer Prevention and Risk Assessment, Department of OVP, Cancer Prevention and Population Sciences, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Vice President, Department of Cancer Prevention and Population Sciences, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Division Head, Department of Division of Cancer Prevention and Population Sciences, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Director, Department of CCSG, Cancer Prevention and Population Sciences, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Division of Cancer Prevention & Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Cancer Prevention and Control Translational Research Molecular Intersections between Cancer and Other Diseases
Education & Training
Degree-Granting Education
| 1994 | Johns Hopkins University School of Hygiene & Public Health, Baltimore, MD, US, Epidemiology/Biostatistics, Masters of Public Health |
| 1985 | Wayne State University School of Medicine, Detroit, MI, US, Medicine, Medical Doctorate |
| 1981 | Wayne State University, Detroit, MI, US, Biological Sciences, Bachelor of Science |
Postgraduate Training
| 2024-2024 | Certified Tobacco Treatment Specialist, Tobacco Treatment Training Certificate Program, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2008-2009 | Advanced Professional Training, Faculty Academic Leadership, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1993-1996 | Research Fellowship, Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD |
| 1991-1993 | Clinical Fellowship, Medical Oncology, University Of California, San Francisco, San Francisco, CA |
| 1985-1988 | Clinical Internship and Residency, Internal Medicine, Emory University Affiliated Hospitals, Atlanta, GA |
Board Certifications
| 2013 | American Board of Internal Medicine - Medical Oncology |
| 2003 | American Board of Internal Medicine - Recertification in Medical Oncology |
| 1993 | American Board of Internal Medicine - Diplomate in Medical Oncology |
| 1988 | American Board of Internal Medicine - Diplomate in Internal Medicine |
| 1986 | National Board of Medical Examiners - Diplomate |
Experience & Service
Academic Appointments
Director, Department of Office of the Director, National Cancer Institute, Bethesda, MD, 2004 - 2007
Chief & Medical Officer, Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1999 - 2004
Medical Officer, Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1997 - 1999
Special Expert (Translational Cancer Prevention), Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1996 - 1997
Administrative Appointments/Responsibilities
Associate Director, Department of CCSG, Community Outreach and Engagement Component, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2024
Department Chair ad interim, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2016
Co-Director, Department of Moonshot Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2024
Department Chair ad interim, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2011
Associate Director, Department of CCSG, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Department Chair ad interim, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2009
Division Head, Department of Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Other Appointments/Responsibilities
Ad Hoc Advisory Consultant, CCSG P30 grant renewal, Northwestern University, Chicago, IL, 2025 - Present
Consultant (Unpaid), Shield™ Blood Test for Colorectal Cancer (CRC) Screening, Guardant Health, Palo Alto, CA, 2024 - 2024
Extramural Reviewer, Division Head Appointment Review, DKFZ Hector Cancer Institute at University Medicine Mannheim, Heidelberg, 2024 - 2024
Member (offered), Expert Review Panel, Cancer Research UK, London, 2024 - 2024
External Advisory Board, U54 SPORE on the Biology of Colorectal Cancer Disparities, Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, 2024 - Present
Member, External Scientific Review Committee for the DKFZ (German National Cancer Research Center), Helmholz Foundation, Heidelberg, 2024 - 2025
Member, Innovation Council, Prevent Cancer Foundation, Alexandria, VA, 2023 - Present
Co-chair, External Scientific Advisory Board, Mayo Clinic, Rochester, MN, 2023 - Present
Member, Task Force to Advance the Care of Sexual and Gender Minority Cancer Patients, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Consultant (paid to MD Anderson), Multi-cancer early detection device development, Exact Sciences, Madison, WI, 2022 - Present
Member, External Advisory Board, Medical University of South Carolina, Charleston, SC, 2021 - Present
Member, External Advisory Board, Oregon Health Sciences University, Portland, OR, 2021 - Present
Member, Lung Moonshot Executive Steering Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Member, External Advisory Board, University of Alabama at Birmingham, Birmingham, AL, 2020 - Present
Chair, External Scientific Advisory Board, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, 2020 - 2020
Member, External Advisory Board for the Virginia Survivor Cohort, Virginia Commonwealth University, Richmond, VA, 2020 - 2021
At-Large Member, Women's Leadership Network Steering Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2023
Champion, Diversity, Equity, and Inclusion, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2023
Member, Howard-Hopkins Partnership Steering Committee (PSC), Sidney Kimmel CCC & Howard University Cancer Center, Baltimore, MD, 2019 - 2020
Extramural advisory, Search Committee for the Director of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, 2019 - 2020
Chair, Community Outreach and Engagement External Advisory Board, Mayo Clinic Cancer Center, Rochester, MN, 2019 - 2019
Member, Clinical and Translational Research Advisory Committee (CTAC), National Cancer Institute, Bethesda, MD, 2019 - 2024
Member, Advisory Group on Multicancer Early Detection Tests - Potential Development Strategies and Uses, Mayo Clinic, Rochester, MN, 2019 - 2021
Member, External Advisory Board, Rutgers University, New Brunswick, NJ, 2019 - Present
Member, External Advisory Board, Virginia Commonwealth University, Richmond, VA, 2019 - 2023
Member, Strategic Planning Working Group (ad hoc), National Cancer Institute, Bethesda, MD, 2019 - 2019
Co-Chair, Internal Advisory Committee, University of Puerto Rico and the University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Member, NCI Ideas Workshop, National Cancer Institute, Bethesda, MD, 2018 - 2019
Member, Physician Scientist Oncology Training Program - External Advisory Committee, UT Southwestern Medical Center, Dallas, TX, 2018 - 2020
Member, External Scientific Advisory Committee, Albert Einstein Cancer Center, Bronx, NY, 2018 - 2020
Member (ad hoc), External Advisory Committee, University of Wisconsin-Madison, Madison, WI, 2018 - 2020
Member, External Advisory Panel, University of New Mexico, Albuquerque, NM, 2017 - Present
Member, External Advisory Panel (ad hoc), Fred Hutchinson Cancer Research Center, Seattle, WA, 2017 - 2017
Member, External Advisory Board, Johns Hopkins University, Baltimore, MD, 2017 - Present
Co-Chair, Cancer Prevention Steering Committee, National Cancer Institute, Bethesda, MD, 2017 - 2023
Participant, Biden's Cancer Moonshot initiative, Blue Ribbon Panel Working Group on Precision, Prevention and Early Detection, Washington, DC, 2016 - 2018
Member, Board of Directors, MD Anderson Physicians Network (MDAPN), Houston, TX, 2015 - 2016
Member, External Advisory Board, University of Nebraska Medical Center, Omaha, NE, 2015 - Present
Member, Board of Directors, CATCH Global Foundation, Austin, TX, 2015 - 2024
Member, Gastric and Esophageal Cancers Working Group, National Cancer Institute, Bethesda, MD, 2015 - 2018
Member, Cancer Center Director Search Committee, University of Texas - Austin, Austin, TX, 2014 - 2015
Member, Advisory Board, Pozen Pharmaceutical Development Company, Raleigh, NC, 2013 - 2014
Member, Process of Care Research Branch (PCRB) Working Group, National Cancer Institute, Rockville, MD, 2012 - 2017
Member, External Advisory Board, The University of Texas - Southwestern, Dallas, TX, 2011 - Present
Consultant, Special Government Employee (SGE), Oncologic Drugs Advisory Committee (ODAC), Food and Drug Administration, Silver Springs, MD, 2010 - 2015
Consultant and committee member, Multilevel Interventions Across the Cancer Care Continuum Committee, National Cancer Institute, Rockville, MD, 2010 - 2013
Consultant, External Cancer Research Review and Center Planning, University of Illinois - Chicago, Chicago, IL, 2010 - Present
Member, CCSG External Advisory Board (ad hoc), University of Arizona Cancer Center, Tucson, AZ, 2009 - 2009
Member, Process to Accelerate Translational Science Working Group (PATS WG), National Cancer Institute, Bethesda, MD, 2009 - 2013
Moderator, Translational Science Meeting, National Cancer Institute, Vienna, VA, 2009 - 2009
Member, Scientific Steering Committee, Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Oxford, 2009 - 2013
Member, Editorial Advisory Board, Prevention Magazine, Emmaus, PA, 2009 - 2014
Member, Extramural Scientific Advisory Committee, Harris County Hospital and University National Children's Study, Houston, TX, 2008 - 2013
Member, External Advisory Board, University of Kansas, Kansas City, KS, 2008 - Present
Member, External Advisory Board, Roswell Park Cancer Institute, Buffalo, NY, 2008 - Present
Member, External Advisory Board, Mayo Clinic, Rochester, MN, 2008 - Present
Member, External Advisory Board, University of Utah, Salt Lake City, UT, 2008 - Present
Member, External Scientific Advisory Board, Ohio State University Comprehensive Cancer Center - James Cancer Hospital, Columbus, OH, 2008 - 2017
Panelist, Translational Science, Indiana Health Industry Forum - Oncology Summit, Indianapolis, IN, 2008 - 2008
Special Advisor on Cancer Prevention, Cancer Institute of New Jersey, Somerset, NJ, 2008 - 2008
Advisor, National Cancer Prevention Initiative, National Cancer Institute of Canada and Canadian Cancer Society, Toronto, Ontario, 2006 - 2008
Executive Secretary, National Cancer Advisory Board - Cancer Centers Subcommittee, National Cancer Institute, Bethesda, MD, 2005 - 2007
Co-chair, Translational Research Working Group, National Cancer Institute, Bethesda, MD, 2005 - 2007
Member, Executive Committee, National Cancer Institute, Bethesda, MD, 2004 - 2007
Co-Leader, Scientific Advances Symposium Planning Project Team, National Cancer Institute, Bethesda, MD, 2002 - 2003
Facilitator, SPORE (P50) Program - Colorectal Cancer Research Program, National Cancer Institute, Bethesda, MD, 2002 - 2004
NCI Representative, Secretary's Initiative on Colorectal Cancer, Department of Health and Human Services, Bethesda, MD, 2002 - 2003
Executive Director, Stomach and Esophageal Cancer Progress Review Group, National Cancer Institute, Bethesda, MD, 2001 - 2005
Member, Flat Adenoma and ACF Project Team, National Cancer Institute, Bethesda, MD, 2001 - 2002
Member, Clinical Trials Project Team, National Cancer Institute, Bethesda, MD, 2000 - 2001
Co-Chair, Working Group on Barrett's-associated Cancer, National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2000 - 2002
Member, Prevention of Languishing Studies Project Team, National Cancer Institute, Bethesda, MD, 2000 - 2001
Member, Cancer Prevention Scientific Education Committee, National Cancer Institute, Bethesda, MD, 2000 - 2001
Member, Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Scientific Coordination & Oversight Panel, National Cancer Institute, Bethesda, MD, 1999 - 2005
Member, Coordinating Unit, National Cancer Institute, Bethesda, MD, 1999 - 2005
Member, Committee on Public Educational Materials for Cancer Prevention, National Cancer Institute, Bethesda, MD, 1997 - 1998
Ad Hoc Member, Community Clinical Oncology Program - Prevention & Control Concept & Protocol Review Committees, National Cancer Institute, Bethesda, MD, 1996 - 2005
NCI Divisional Representative, International Common Toxicity Criteria Revision Committee (Version 2.0), National Cancer Institute, Bethesda, MD, 1996 - 1997
Ad Hoc Member, Chemoprevention Safety and Protocol Review Committee, National Cancer Institute, Bethesda, MD, 1994 - 2005
Member, Chemoprevention Agent Development Committee, National Cancer Institute, Bethesda, MD, 1994 - 2005
Member and Chair, Source Evaluation Groups for Phase II Chemoprevention Trials, National Cancer Institute, Bethesda, MD, 1994 - 1999
Institutional Committee Activities
Member, Executive Committee, iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium, 2024 - Present
Member, Texas Health Equity Alliance for Breast Cancer (THEAL) Internal Advisory Committee, 2023 - Present
Past Chair, Division Heads, 2023 - 2024
Member, Texas Business Women's Committee, 2022 - 2023
Observer/advisor, Policy Management System Renovation Project, 2022 - Present
Chair, Division Heads, 2022 - 2023
Team Lead - Clinical Prevention Services, Service Line Teams, 2021 - Present
Incoming Chair, Division Heads, 2021 - 2022
Co-Chair, Rogers Award Selection Committee - Prevention, 2021 - 2021
Member, Research Policy Advisory Council, 2021 - Present
Member, Academic Policy Advisory Council, 2021 - Present
Member, Global Oncology Strategy Workgroup, 2021 - Present
Member, Research Enablement, Activities and Conduct Team (REACT), 2021 - Present
Member, Cancer Screening Task Force, 2021 - Present
Member, Strategic Position Management Committee, 2020 - 2022
Member, Strategic Position Management Committee - Classified research and education positions, 2020 - Present
Member, Promoting HPV Vaccination Among Texas Young Adults, 2020 - Present
Faculty Co-lead, Board of Visitors Cancer Prevention Committee, 2020 - Present
Member, Sarcoma SPORE, 2019 - Present
Member, Executive Committee, Komen Training Program to Reduce Breast Cancer Disparities in Black and Hispanic Women, 2018 - 2020
Member, Internal Advisory Board, 2018 - 2021
Member, Network Advisory Committee, 2018 - Present
At-Large Member, Women's Leadership Network Steering Committee, 2018 - 2022
Member, President's Advisory Committee, 2018 - Present
Division Head for Cancer Prevention & Population Sciences, Division Heads, 2018 - Present
Member, Quasi-Endowment for the Underserved (COE Fund), 2018 - Present
Member, Mexican-American Cohort Study, 2018 - Present
Co-Chair, Clinician Scientist Advisory Committee, 2017 - 2017
Member, Shared Resource Executive Committee, 2017 - 2019
Member, Institutional Biospecimen Utilization Committee (IBUC), 2017 - Present
Member, Head & Neck SPORE (P50), 2016 - Present
Chair, 2016 Rogers Award, 2016 - 2016
Chair, HPV SPORE (P50), 2016 - 2018
Co-leader and Convener, CCSG Community Outreach & Engagement Leaders Team, 2016 - 2022
Member, Women and Minority Faculty Inclusion, 2016 - 2023
Member, Executive Clinical Operations Team, 2015 - 2019
Member, International Cancer Control Partnership Steering Committee, 2015 - 2022
Member, MD Anderson Communications Advisory Committee, 2015 - 2017
Member, Cancer Medicine Division Head Search Committee, 2014 - 2015
Member, GAP 2015 Conference, 2014 - 2015
Member, Women Faculty Programs' Advisory Committee, 2014 - 2016
Member, Prostate Cancer SPORE (P50), 2014 - 2021
Member, Medical Quality Planning Committee, 2014 - 2019
Team Member, Translational Research Strategic Planning Committee, 2014 - 2016
Member, GAP International Advisory Board, 2014 - 2016
Member, Head and Neck Cancer SPORE (P50), 2013 - Present
Co-Chair, Internal Medicine Division Head Search Committee, 2013 - 2014
Member, Clinical/Translational Awards Committee, 2013 - 2016
Member, Institutional Research Executive Committee (IREC), 2013 - 2015
Member, Thoracic Head and Neck Medical Oncology Chair Search Committee, 2012 - 2013
Member, David H. Koch Center for Prostate Cancer, 2012 - 2017
Member, Research Station, 2012 - 2014
Member, External Communications Advisory Committee, 2012 - 2017
Member, Institute for Cancer Care Excellence, 2012 - 2017
Member, Standing Committee on Faculty Awards, 2012 - Present
Member, EVP and Provost Search Advisory Committee, 2012 - 2013
Member, Epidemiology Search Committee, 2011 - 2013
Member, Institutional Clinical Executive Committee, 2011 - 2015
Session Co-Chair, Annual Symposia on Cancer Research, 2010 - 2010
Co-Chair, Cancer Control Leadership Team, 2010 - 2024
Co-Leader, GI Cancer Research Program, 2010 - 2022
Member, Molecular Testing Evaluation Committee, 2010 - Present
Member, MD Anderson Survival Monograph Editorial Board, 2009 - 2009
Member, Global Academic Programs Oversight Steering Committee, 2009 - 2014
Chair, Comparative Effectiveness Research Grants Review Committee, 2009 - 2011
Member, Institutional Awards Committee, 2009 - Present
Chair, Duncan Institute Executive Committee, 2009 - Present
Member, Management Committee, 2008 - 2011
Member, CCSG Internal Advisory Board, 2008 - Present
Member, Margaret L. Kripke Legends Award, 2008 - Present
Member, Cancer Prevention Research Training Program Advisory Committee, 2008 - Present
Member, Division Heads Committee, 2008 - 2012
Member, 2008 Rogers Award, 2008 - 2008
Member, Institute of Personalized Cancer Therapy (IPCT), 2008 - 2015
Member, Infrastructure/Animal Care Committee, 2008 - 2010
Member, Research Strategies Advisory Committee, 2007 - 2012
Member, Clinical Research Council, 2007 - 2011
Member, Translational Research Faculty Development Committee, 2007 - 2012
Member, Extramural Programs Oversight Steering Committee, 2007 - 2014
Member, PRS Executive Council, 2007 - Present
Member, Research Council, 2007 - 2013
Member, Clinical Strategies Advisory Committee, 2007 - 2012
Member, President's Advisory Board, 2007 - 2015
Member, Executive Committee of the Medical Staff, 2007 - Present
Member, CCSG Executive Committee, 2007 - Present
Honors & Awards
| 2015 | ASCO/American Cancer Society Award and Lecture, ASCO/American Cancer Society |
| 2015 | 2015 Provost's Distinguished Faculty Mentor Nominee, The University of Texas MD Anderson Cancer Center |
| 2014 | Cancer Prevention Fellowship Distinguished Alumni Award, National Cancer Institute, Department of Health & Human Services |
| 2013 | Eagle Award, Cancer Fighters of Houston, Inc |
| 2011 | Outstanding Leading Mentor in Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center |
| 2007 | On-the-Spot Award, National Cancer Institute |
| 2007 | The Nancy Terner Behrman Lecture in Honor of Betty Flehinger, PhD, Weill Cornell Medical School, NYC |
| 2003 | Service Award, National Cancer Institute |
| 2002 | Research Award, Distinguished Achievement in Cancer Prevention, National Cancer Institute |
| 2002 | Research Award, PLCO Ancillary Studies Project Team (Group Award), National Cancer Institute |
| 2002 | On-the-Spot Award, National Cancer Institute |
| 2000 | Performance Awards, Department of Health and Human Services |
| 1999 | On-the-Spot Award, National Cancer Institute |
| 1999 | Performance Awards, Department of Health and Human Services |
| 1998 | Performance Awards, Department of Health and Human Services |
| 1996 | Scholarship, AACR/ASCO (First Joint) Workshop - Methods in Clinical Cancer Research, Park City, Utah |
| 1994 | Delta Omega Public Health Honor Society, Johns Hopkins Alpha Chapter |
| 1988 | Outstanding, Emory University - Annual House Staff Evaluation Committee designations |
| 1987 | Outstanding, Emory University - Annual House Staff Evaluation Committee designations |
| 1986 | Outstanding, Emory University - Annual House Staff Evaluation Committee designations |
| 1985 | Outstanding, Emory University - Annual House Staff Evaluation Committee Designations |
| 1981 | Scholarship (Full Tuition), Wayne State University |
| 1981 | Phi Beta Kappa, Wayne State University |
| 1981 | Honors Program, Wayne State University, College of Liberal Arts |
| 1980 | Honors Program, Wayne State University, College of Liberal Arts |
| 1980 | Scholarship (Full Tuition), Wayne State University |
| 1979 | Scholarship (Full Tuition), Wayne State University |
| 1979 | Honors Program, Wayne State University, College of Liberal Arts |
| 1978 | Scholarship (Full Tuition), Wayne State University |
| 1978 | Honors Program, Wayne State University, College of Liberal Arts |
| 1977 | Scholarship (Full Tuition), Wayne State University |
| 1977 | Honors Program, Wayne State University, College of Liberal Arts |
| 1977 | Valedictorian, Madison High School |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Love, B, Coffman, R, Ghosh, C, Cofer, J, Hurst, A, Hawk, E, et al. Implementation and Evaluation of a Multi-level, Place-Based Tobacco Prevention and Control Program at a Minority-Serving Institution in Texas. Prevention Science 25(6):898-909, 2024. PMID: 39060839.
- Schrank BR, Fuller JA, Gallagher CM, Morris VK, Holliday EB, Hawk E, et al. Institution-wide retreats foster organizational learning and action at a comprehensive cancer center. J Cancer Educ 39(4):368-373, 2024. e-Pub 2024. PMID: 38468110.
- Hassan MM, Li D, Han Y, Byun J, Hatia RI, Hawk, E, et al. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. PMID: 38381705.
- Torres HA, Mustafayev K, Juneau RP, Hwang JP, Wang LS, Hawk E, et al. Implementation of universal hepatitis c virus screening in a tertiary cancer center. J Natl Compr Canc Netw 22(2D):e237332, 2024. PMID: 38729204.
- Rechis R, Oestman KB, Walsh MT, Love B, Hawk E. Be Well™ Acres Homes: A community-driven, evidence-based approach to reduce health inequities through sustained cross-sector partnership. Cancer Causes Control 35(4):611-622, 2024. e-Pub 2023. PMID: 37979072.
- Oestman, KB, Rechis, R, Williams, PA, Brown, JA, Treiman, K, Hawk, E, et al. Reducing risk for chronic disease: Evaluation of a collective community approach to sustainable evidence-based health programming. BMC Public Health 24(1):240, 2024. PMID: 38245669.
- Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Hawk ET, et al. Exercise training reduces the inflammatory response and promotes intestinal mucosa-associated immunity in Lynch syndrome. Clin Cancer Res 29(21):4361-4372, 2023. e-Pub 2023. PMID: 37724990.
- Batman SH, Varon ML, Daheri M, Ogburn T, Rivas SD, Hawk E, et al. Addressing cervical cancer disparities in Texas: Expansion of a community-based prevention initiative for medically underserved populations. Prev Med Rep 36:102486, 2023. e-Pub 2023. PMID: 38021412.
- Hatia RI, Eluri M, Hawk ET, Shalaby A, Karatas E, Shalaby A, et al. Independent of primary sclerosing cholangitis and cirrhosis, early adulthood obesity is associated with cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 32(10):1338-1347, 2023. e-Pub 2023. PMID: 37540502.
- Bello RS, Bello RS, Walsh MT, Walsh MT, Harper B, Harper B, Amos CE, Amos CE, Oestman K, Oestman K, Hawk E, Hawk E, et al, et al. Creating and activating an implementation community to drive HPV vaccine uptake in Texas: The role of an NCI-designated cancer center. Vaccines (Basel) 11(6), 2023. e-Pub 2023. PMID: 37376517.
- Torode JS, Tittenbrun Z, Romero Y, Johnson SE, Bourque JM, Hawk E, et al. Ten years of the international cancer control partnership: promoting national cancer control plans to shape the health system response for cancer control. JCO Glob Oncol 9, 2023. PMID: 36630665.
- Salcedo MP, Gowen R, Rodriguez AM, Fisher-Hoch S, Daheri M, Hawk E, et al. Addressing high cervical cancer rates in the Rio Grande Valley along the Texas-Mexico border: a community-based initiative focused on education, patient navigation, and medical provider training/telementoring. Perspect Public Health 143(1):22-28, 2023. e-Pub 2021. PMID: 34130548.
- Fokom Domgue J, Pande M, Yu R, Manjuh F, Welty E, Hawk E, et al. Development, implementation, and evaluation of a distance learning and telementoring program for cervical cancer prevention in Cameroon. JAMA Netw Open 5(11):e2240801, 2022. e-Pub 2022. PMID: 36346631.
- Berenson AB, Chang M, Hawk ET, Ramondetta LM, Hoang T. Vulvar cancer incidence in the US and its relationship to human papillomavirus vaccinations, 2001-2018. Cancer Prev Res (Phila) 15(11):777-784, 2022. e-Pub 2022. PMID: 35969832.
- Kwan SY, Sabotta CM, Joon A, Wei P, Petty LE, Hawk ET, et al. Gut microbiome alterations associated with diabetes in Mexican Americans in South Texas. mSystems 7(3):e0003322, 2022. e-Pub 2022. PMID: 35477306.
- Kwan SY, Jiao J, Joon A, Wei P, Petty LE, Hawk ET, et al. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology 75(4):955-967, 2022. e-Pub 2021. PMID: 34633706.
- Kisiel JB, Papadopoulos N, Liu MC, Crosby D, Srivastava S, Hawk ET. Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questions. Cancer 128 Suppl 4(S4):861-874, 2022. PMID: 35133659.
- Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Hawk ET, et al. Circulating fatty acids associated with advanced liver fibrosis and hepatocellular carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 30(9):1643-1651, 2021. e-Pub 2021. PMID: 34155064.
- Rechis R, Oestman KB, Caballero E, Brewster A, Walsh MT, Hawk E, et al. Be Well Communities™: Mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes Control 32(8):859-870, 2021. e-Pub 2021. PMID: 34037915.
- Hawk ET, Maresso KC. The ASPREE trial: An unanticipated stimulus for greater precision in prevention?. J Natl Cancer Inst 113(3):221-222, 2021. e-Pub 2020. PMID: 32778864.
- Guimarães DP, Mantuan LA, de Oliveira MA, Junior RLH, Mafra da Costa A, Hawk ET, et al. The performance of colorectal cancer screening in Brazil: the first two years of the implementation program in Barretos Cancer Hospital. Cancer Prev Res (Phila) 14(2):241-252, 2021. e-Pub 2020. PMID: 32998941.
- Tami-Maury I, Suchil L, Reynales-Shigematsu LM, Garcia-Gomez L, Chen M, Hawk E, et al. Cross-sectional survey for assessing cancer care providers' characteristics and attitudes on smoking cessation in Colombia and Mexico. BMJ Open 11(2):e041447, 2021. e-Pub 2021. PMID: 33526497.
- Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Hawk ET, et al. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: A cross-sectional study. Support Care Cancer 29(1):97-105, 2021. e-Pub 2020. PMID: 32314052.
- Kripke M, Brody JG, Hawk E, Hernandez AB, Hoppin PJ, Rudel RA, et al. Rethinking environmental carcinogenesis. Cancer Epidemiol Biomarkers Prev 29(10):1870-1875, 2020. PMID: 33004408.
- Davis JS, Kanikarla-Marie P, Gagea M, Yu PL, Fang D, Hawk E, et al. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 20(1):871, 2020. e-Pub 2020. PMID: 32912193.
- Liao Y, Basen-Engquist KM, Urbauer DL, Bevers TB, Hawk E, Schembre SM. Using continuous glucose monitoring to motivate physical activity in overweight and obese adults: A pilot study. Cancer Epidemiol Biomarkers Prev 29(4):761-768, 2020. e-Pub 2020. PMID: 32066620.
- Abu-Sbeih H, Ali FS, Qiao W, Lum P, Shafi MA, Hawk E, et al. Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. J Cancer 11(11):3192-3198, 2020. e-Pub 2020. PMID: 32231724.
- Chido-Amajuoyi OG, Mantey D, Cunningham S, Yu R, Kelder S, Hawk E, et al. Characteristics of US adults attempting tobacco use cessation using e-cigarettes. Addict Behav 100:106123, 2020. e-Pub 2019. PMID: 31605837.
- Hawk ET, Colbert Maresso K. E-Cigarettes: Unstandardized, under-regulated, understudied - and unknown health and cancer risks. Cancer Res 79(24):6079-6083, 2019. e-Pub 2019. PMID: 31658978.
- Fokom Domgue J, Baker E, Manjuh F, Lopez M, Welty T, Cameroon Cervical Cancer Prevention ECHO collaborative group, et al. Connecting frontline providers in Africa with distant experts to improve patients' outcomes through Project ECHO: a successful experience in Cameroon. Int J Gynecol Cancer 29(9):1446-1447, 2019. e-Pub 2019. PMID: 31118215.
- Hernandez M, Hernández-Valero MA, García-Prieto C, Patterson DG, Hajek RA, Hawk E, et al. A pilot study evaluating organochlorine and organophosphate pesticide exposure in children and adolescents of Mexican descent residing in Hidalgo County, Texas. J Immigr Minor Health 21(4):751-760, 2019. e-Pub 2018. PMID: 30066057.
- Coletta AM, Marquez G, Thomas P, Thoman W, Bevers T, Hawk E, et al. Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors. PLoS One 14(8):e0220814, 2019. e-Pub 2019. PMID: 31369653.
- Huey RW, Hawk E, Offodile AC. Mind the gap: Precision oncology and its potential to widen disparities. J Oncol Pract 15(6):301-304, 2019. e-Pub 2019. PMID: 31112478.
- Delacruz RGC, Sandoval IT, Chang K, Miller BN, Reyes-Uribe L, Hawk ET, et al. Functional characterization of CNOT3 variants identified in familial adenomatous polyposis adenomas. Oncotarget 10(39):3939-3951, 2019. e-Pub 2019. PMID: 31231471.
- Mackert M, Case K, Lazard A, Oh J, Wagner JH, Hawk E, et al. Building a health communication brand for University of Texas System tobacco control. J Am Coll Health 67(4):291-298, 2019. e-Pub 2018. PMID: 29952736.
- Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Hawk ET, et al. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine 42:296-303, 2019. e-Pub 2019. PMID: 30905849.
- Zacharias NM, Ornelas A, Lee J, Hu J, Davis J, Hawk E, et al. Real-time interrogation of aspirin reactivity, biochemistry, and biodistribution by hyperpolarized magnetic resonance spectroscopy. Angew Chem Int Ed Engl 58(13):4179-4183, 2019. e-Pub 2019. PMID: 30680862.
- Cunningham SA, Yu R, Shih T, Giordano S, McNeill LH, Hawk E, et al. Cancer-related risk and beliefs in Texas: Findings from a 2018 population-level survey. Cancer Epidemiol Biomarkers Prev 28(3):486-494, 2019. e-Pub 2019. PMID: 30700446.
- Dahlstrom KR, Sturgis EM, DePinho RA, Hawk E, Baum G. Knowledge about the human papillomavirus vaccine among employees at a tertiary cancer center: room for improvement. J Appl Res Child 10(2):Article 5, 2019. PMID: None.
- Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Hawk ET, et al. AACR white paper: Shaping the future of cancer prevention - a roadmap for advancing science and public health. Cancer Prev Res (Phila) 11(12):735-778, 2018. PMID: 30530635.
- Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Hawk ET, et al. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol 29(10):2061-2067, 2018. PMID: 30412224.
- Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, et al. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. PMID: 30112590.
- Frech S, Muha CA, Stevens LM, Trimble EL, Brew R, Hawk ET, et al. Perspectives on strengthening cancer research and control in Latin America through partnerships and diplomacy: Experience of the National Cancer Institute's Center for Global Health. J Glob Oncol 2018(4):1-11, 2018. e-Pub 2018. PMID: 30241245.
- Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Hawk ET, et al. Immune profiling of premalignant lesions in patients with Lynch syndrome. JAMA Oncol 4(8):1085-1092, 2018. PMID: 29710228.
- Lin SH, Raju GS, Huff C, Ye Y, Gu J, Hawk E, et al. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. PMID: 28607096.
- Foxhall L, Moreno M, Hawk E. MD Anderson's population health approaches to cancer prevention. Tex Med 114(2):34-41, 2018. e-Pub 2018. PMID: 29393960.
- Sivakumar S, San Lucas FA, McDowell TL, Lang W, Xu L, Hawk ET, et al. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res 77(22):6119-6130, 2017. e-Pub 2017. PMID: 28951454.
- Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Hawk E, et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
- Gausachs M, Borras E, Chang K, González S, Azuara D, Hawk E T, et al. Mutational heterogeneity in APC and KRAS arises at the crypt level and leads to polyclonality in early colorectal tumorigenesis. Clin Cancer Res 23(19):5936-5947, 2017. e-Pub 2017. PMID: 28645942.
- Lopez MS, Baker ES, Milbourne AM, Gowen RM, Rodriguez AM, Hawk ET, et al. Project ECHO: A telementoring program for cervical cancer prevention and treatment in low-resource settings. J Glob Oncol 3(5):658-665, 2017. e-Pub 2016. PMID: 29094102.
- Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawk E, et al. Beyond COX-1: The effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev 36(2):289-303, 2017. e-Pub 2017. PMID: 28762014.
- Hurd TC, Kaplan CD, Cook ED, Chilton JA, Lytton JS, Hawk ET, et al. Building trust and diversity in patient-centered oncology clinical trials: An integrated model. Clin Trials 14(2):170-179, 2017. e-Pub 2017. PMID: 28166647.
- Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Hawk ET, et al. Use of non-steroidal anti-inflammatory drugs in US adults: Changes over time and by demographic. Open Heart 4(1):e000550, 2017. e-Pub 2017. PMID: 28674622.
- Hawk ET. Ernest Hawk discusses the NCI-designated cancer centers' joint statement on the HPV vaccine. Oncology (Williston Park) 30(7):599-600, 2016. PMID: 27422108.
- Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Hawk ET, et al. Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res (Phila) 9(6):417-427, 2016. e-Pub 2016. PMID: 27221540.
- Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Hawk ET, et al. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol 45(3):713-713F, 2016. e-Pub 2015. PMID: 26686840.
- DePinho RA, Hawk E. Cancer prevention in developing countries: a vision for preserving health in Mexico. Salud Publica Mex 58(2):93-96, 2016. PMID: 27557366.
- Hildebrandt MA, Reyes ME, Lin M, He Y, Nguyen SV, Hawk ET, et al. Germline genetic variants in the Wnt/beta-catenin pathway as predictors of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 25(3):540-546, 2016. e-Pub 2016. PMID: 26809274.
- Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Hawk E, et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 65(2):286-295, 2016. e-Pub 2015. PMID: 25792707.
- Tsai KY, Hawk ET. When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design. Cancer Prev Res (Phila) 9(2):125-127, 2016. e-Pub 2015. PMID: 26714773.
- Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Hawk ET, et al. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 2016. PMID: 27574101.
- Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin 65(5):345-383, 2015. e-Pub 2015. PMID: 26284997.
- Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, Hawk E, et al. Obesity early in adulthood increases risk but does not affect outcomes of Hepatocellular Carcinoma. Gastroenterology 149(1):119-129, 2015. e-Pub 2015. PMID: 25836985.
- Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood A, Hawk ET. Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?. Cancer Prev Res (Phila) 7(10):973-992, 2014. e-Pub 2014. PMID: 25060262.
- Satcher RL, Bogler O, Hyle L, Lee A, Simmons A, Williams R, Hawk E, Matin S, Brewster AM. Telemedicine and telesurgery in cancer care: Inaugural conference at MD Anderson Cancer Center. J Surg Oncol 110(4):353-359, 2014. e-Pub 2014. PMID: 24889208.
- Akiyama J, Akiyama J, Alexandre L, Alexandre L, Baruah A, Baruah A, Buttar N, Buttar N, Chandra R, Chandra R, Hawk E, Hawk E, et al, et al. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci 1325(1):108-26, 2014. PMID: 25266020.
- Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient?. JAMA 312(12):1193-4, 2014. PMID: 25247511.
- Herbst RS, Hobin JA, Gritz ER, on Tobacco WCFTAS, Cancer [Hawk E, WK] H. AACR celebrates 50 years of tobacco research and policy. Clin Cancer Res 20(7):1709-18, 2014. PMID: 24691637.
- Hawk ET, Habermann EB, Ford JG, Wenzel JA, Brahmer JR, Chen MS, et al. Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: A current view and opportunities for improvement. Cancer 120 Suppl S7:1113-1121, 2014. PMID: 24643649.
- Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, et al. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 34(12):2750-6, 2013. e-Pub 2013. PMID: 23996928.
- Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, APC Trial Collaborators APC, Kubo M, et al.. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res 19(23):6430-7, 2013. e-Pub 2013. PMID: 24084763.
- Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Mol Carcinog 52 Suppl 1(SUPPL1):139-47, 2013. e-Pub 2013. PMID: 23776098.
- Coxib, (CNT) Collaboration TNT, Bhala N, Emberson J, Merhi A, Hawk E, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769-79, 2013. e-Pub 2013. PMID: 23726390.
- Raju GS, Vadyala V, Slack R, Krishna SG, Ross WA, Hawk E, et al. Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med 2(3):391-402, 2013. e-Pub 2013. PMID: 23930215.
- Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hawk E, et al. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) 6(3):196-205, 2013. PMID: 23466817.
- Kumar NB, Dhurandhar M, Aggarwal B, Anant S, Daniel K, Hawk E, et al. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med 2(1):108-15, 2013. PMID: 24279005.
- Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, et al. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer 118(24):6188-6198, 2012. e-Pub 2012. PMID: 22673945.
- Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Hawk E, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 104(20):1599-611, 2012. PMID: 23073549.
- Dai J, Gu J, Huang M, Eng C, Kopetz ES, Hawk E, et al. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 2012. e-Pub 2012. PMID: 22505654.
- Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Hawk ET, et al. Genetic polymorphisms in MicroRNA-Related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res 18(14):3982-91, 2012. e-Pub 2012. PMID: 22661538.
- Cialdella-Kam L, Sabado P, Bispeck MK, Silverman S, Bernstein L, Hawk E, et al. Implementing Cancer Prevention into Clinical Practice. J Cancer Educ 27(Suppl 2):S136-43, 2012. e-Pub 2012. PMID: 22367592.
- Lin M, Eng C, Hawk E, Huang M, Greisinger AJ, Gu J, et al. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis 33(4):841-7, 2012. e-Pub 2012. PMID: 22318908.
- Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Hawk ET, et al. The APC and PreSAP Trials: A Post Hoc Noninferiority Analysis Using a Comprehensive New Measure for Gastrointestinal Tract Injury in 2 Randomized, Double-Blind Studies Comparing Celecoxib and Placebo. Clin Ther 34(3):569-79, 2012. e-Pub 2012. PMID: 22386831.
- Lin J, Forman MR, Wang J, Grossman HB, Chen M, Hawk ET, et al. Intake of red meat and heterocyclic amines, metabolic pathway genes, and bladder cancer risk. Int J Cancer 131(8):1892-1903, 2012. e-Pub 2012. PMID: 22261697.
- Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma. Cancer Prev Res (Phila) 5(1):61-72, 2012. e-Pub 2011. PMID: 22030088.
- Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, PLCO Project Team, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125-32, 2012. e-Pub 2012. PMID: 22228146.
- Ross W, Lynch P, Raju G, Rodriguez A, Burke T, Hawk E, et al. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer 3(1):16-22, 2012. PMID: 22893787.
- Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) 4(11):1728-35, 2011. e-Pub 2011. PMID: 21778329.
- Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment. Cancer Prev Res (Phila) 4(8):1172-80, 2011. PMID: 21816845.
- Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, PLCO Project Team, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305(22):2295-303, 2011. PMID: 21642681.
- Lin M, Hawk E, Huang M, Lin J, Gu J, Ellis LM, et al. Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC). J Clin Oncol 29(15_suppl):3529, 2011. PMID: 28020328.
- Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, et al. Chromosomal Aberrations Predict Malignant Progression of Esophageal Adenocarcinoma: a Genome-wide High-Density SNP Array Analysis. Cancer Prev Res (Phila) 3(9):1176-86, 2010. e-Pub 2010. PMID: 20651033.
- Brewster AM, Patterson SL, Forman MR, Hughes-Halbert C, Limburg PJ, Hawk ET, et al. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila Pa) 3(8):1044-8, 2010. e-Pub 2010. PMID: 20663980.
- Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 105(6):1437-43, 2010. e-Pub 2010. PMID: 20234350.
- Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 3(5):588-96, 2010. e-Pub 2010. PMID: 20403998.
- Hawk E, Patterson S. Modelling a dream: the molecular prevention of pancreatic cancer. Gut 59(5):566-8, 2010. PMID: 20427387.
- Chan AT, Zauber AG, Meier H, Breazna A, Hunter DJ, Hawk ET, et al. Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma. Gastroenterology 136(7):2127-2136.e1, 2009. e-Pub 2009. PMID: 19233181.
- Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Hawk E, et al. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol 7(5):568-74, 2009. PMID: 19418605.
- Bertagnolli MM, Bertagnolli MM, Eagle CJ, Eagle CJ, Zauber AG, Zauber AG, Redston M, Redston M, Breazna A, Breazna A, Hawk ET, Hawk ET, et al, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2(4):310-21, 2009. e-Pub 2009. PMID: 19336730.
- Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, PLCO Project Team, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-9, 2009. e-Pub 2009. PMID: 19297565.
- Mutch MG, Mph RE, Fleshman JW, Rall CJ, Dry S, Hawk E, et al. A Multi-Center Study of Prevalence and Risk Factors for Aberrant Crypt Foci. Clin Gastroenterol Hepatol 7(5):568-574, 2009. e-Pub 2009. PMID: 19418605.
- Hawk E, Guillem JG. Improving the Vision of Colonoscopy: Does the Fine Print Really Matter?. Cancer Prev Res (Phila) 1(7):495-498, 2008. PMID: 19138997.
- Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET, et al. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res 14(18):5672-7, 2008. PMID: 18794074.
- Hawk ET, Matrisian LM, Nelson WG, Dorfman GS, Stevens L, Kwok J, et al. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res 14(18):5664-71, 2008. e-Pub 2008. PMID: 18612047.
- Hawk ET, Greenwood A, Gritz ER, McTiernan A, Sellers T, Hursting SD, et al. The Translational Research Working Group developmental pathway for lifestyle alterations. Clin Cancer Res 14(18):5707-13, 2008. PMID: 18794079.
- Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Hawk ET, et al. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 1(1):21-31, 2008. e-Pub 2008. PMID: 19138933.
- Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial. Cancer Prev Res (Phila Pa) 1(1):32-38, 2008. PMID: 18841250.
- Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Hawk E, et al. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials The Cross Trial Safety Analysis. Circulation 117(16):2104-13, 2008. e-Pub 2008. PMID: 18378608.
- Hawk ET, Viner JL. Statins in esophageal cancer cell lines: promising lead?. Am J Gastroenterol 103(4):838-41, 2008. e-Pub 2008. PMID: 18371147.
- Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Hawk E, et al. Secondary chemoprevention of Barrett's Esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99(7):545-557, 2007. PMID: 17405999.
- Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Hawk ET, et al. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 3(1):1-33, 2007. PMID: 17655039.
- Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Hawk E, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114(10):1028-1035, 2006. PMID: 16943394.
- Hawk ET, Viner JL. Do statins prevent cancer?. Nat Clin Pract Oncol 3(9):478-9, 2006. PMID: 16955084.
- Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Hawk ET, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873-84, 2006. PMID: 16943400.
- Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Hawk ET, et al. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res 66(13):6851-60, 2006. PMID: 16818663.
- Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Hawk E, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15(7):1382-1391, 2006. PMID: 16835340.
- Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Hawk ET, et al. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 15(5):1046-7, 2006. PMID: 16702392.
- Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 129(3):863-73, 2005. PMID: 16143126.
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Hawk E, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-80, 2005. e-Pub 2005. PMID: 15713944.
- Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Hawk E, et al. Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol 22(19):3848-51, 2004. e-Pub 2004. PMID: 15353541.
- Lam S, leRiche JC, McWilliams A, Macaulay C, Dyachkova Y, Hawk E, et al. A randomized phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 10(19):6502-11, 2004. PMID: 15475437.
- Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 127(3):838-44, 2004. PMID: 15362039.
- Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24(5B):3177-84, 2004. PMID: 15510608.
- Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Hawk ET, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 13(6):920-7, 2004. PMID: 15184247.
- Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Hawk ET, et al. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64(8):2904-9, 2004. PMID: 15087410.
- Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Hawk ET, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261-8, 2004. PMID: 14970275.
- Viner JL, Hawk E. Commentary on Chan, et al. N Am Menopause Soc J 11(3):None, 2004. PMID: None.
- Hawk ET, Viner JL. Aspirin: still learning about the wonder drug. Gut 52(11):1535-6, 2003. PMID: 14570718.
- Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM. Frontiers in cancer prevention research. Cancer Res 63(18):5649-55, 2003. PMID: 14522879.
- Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Hawk E, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 12(8):755-62, 2003. PMID: 12917207.
- Hawk E, Viner JL, Umar A, Anderson WF, Sigman C, Guyton KZ. Cancer and the cyclo-oxygenase enzyme: implications for treatment and prevention. Amer J Cancer 2(None):27-55, 2003. PMID: None.
- Anderson WF, Guyton KZ, Hiatt RA, Vernon SW, Levin B, Hawk E. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst 94(15):1126-1133, 2002. PMID: 12165637.
- Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Hawk E, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 94(13):1001-9, 2002. PMID: 12096085.
- Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50(6):857-60, 2002. PMID: 12010890.
- Dimitrov NV, Leece CM, Tompkins ER, Seymour E, Bennink M, Hawk E, et al. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev 10(3):201-8, 2001. PMID: 11303588.
- Hawk ET, Hawk ET, Viner JL, Viner JL, Anderson BF, Anderson BF. Development of COX inhibitors as cancer chemopreventives. ASCO Educational Book None(None):28-37, 2001. PMID: None.
- Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946-52, 2000. PMID: 10874062.
- Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60(7):1864-70, 2000. PMID: 10766173.
- Hawk E, Limburg P, Lubet R. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86(11 Suppl):2551-63, 1999. PMID: 10630181.
- Lam S, leRiche JC, Zheng Y, Coldman A, MacAulay C, Hawk E, et al. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst 91(8):691-6, 1999. PMID: 10218506.
- Li H, Schut HA, Conran P, Kramer PM, Lubet RA, Hawk E, et al. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 20(3):425-30, 1999. PMID: 10190557.
- Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 20(2):185-91, 1999. PMID: 10069452.
- Hawk ET, Limburg PJ. Agent development in colorectal cancer chemoprevention: current status and future trends. ASCO Educational Book None(None):193-9, 1999. PMID: None.
- Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Hawk E, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 470:45-53, 1999. PMID: 10709673.
- Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem 44(2):420-7, 1998. PMID: 9474054.
- Hawk E, Doeltz MK, Kelloff GK. Indomethacin - toxicology and safety. Contribution to IARC Handbooks of Cancer Prevention - Non-steroidal Anti-inflammatory Drugs (International Agency for Research on Cancer, Lyon) 1:151-197, 1997. PMID: None.
- Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Steele VE, Lubet RA, et al. Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev 5(2 Suppl):79-85, 1996. PMID: 9061299.
- Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen, and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17(7):1435-8, 1996. PMID: 8706245.
- Kelloff G, Kelloff G, Boone C, Boone C, Steele V, Steele V, Crowell J, Crowell J, Lubet R, Lubet R, Hawk E, Hawk E, et al, et al. Mechanistic considerations in the evaluation of chemopreventive data. IARC Sci Publ(139):203-19, 1996. PMID: 8923032.
- Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Hawk ET, et al. New agents for cancer chemoprevention. J Cell Biochem Suppl 26(SUPPL. 26):1-28, 1996. PMID: 9154166.
- Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, et al. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl 63(26 Suppl):54-71, 1996. PMID: 9154168.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Malone WF, et al. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl 25:1-14, 1996. PMID: 9027592.
- Kelloff G, Boone C, Crowell J, Nayfield S, Hawk E, Steele VE, et al. Development of breast cancer chemopreventive drugs. Breast J 1(None):271-83, 1995. PMID: None.
Invited Articles
- Cofer J, Hurst AN, Winter T, Moreno M, Cinciripini PM, Hawk E, et al. A comprehensive program to reduce tobacco-related cancers through actions by a national cancer institute-designated cancer center. Cancer Control 29, 2022. PMID: 36373741.
- Maresso KC, Hawk ET. A new year, a healthier you: 5 actions to reduce your cancer risk. Magazine of the National Association of Petroleum Engineers (NAPE) None(January 2020):42-44, 2020. PMID: None.
- Colbert Maresso K, Vilar E, Hawk ET. Urinary PGE-M in colorectal cancer: predicting more than risk?. Cancer Prev Res (Phila) 7(10):969-972, 2014. e-Pub 2014. PMID: 25070664.
- Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Hawk ET, et al. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res 3(4):505-17, 2010. e-Pub 2010. PMID: 20354165.
- Hawk E, Patterson S. Aspirin: anti-colorectal adenocarcinoma activity in the adjuvant arena?. Future Oncol 6(2):197-200, 2010. PMID: 20146578.
- Hawk E, Patterson S. Statins: assessing their effects on cancer risk. NYP Cancer Prevention Newsletter None(14):None, 2010. PMID: None.
Other Articles
- Srivastava S, Faupel-Badger J, Kohaar I, Bahl M, Chan A, Hawk E, et al Defining precancer: a grand challenge for the cancer community. Nat Rev Cancer 24(None):792-809, 2024. PMID: None.
- Maresso KC, Maitra A, Hawk E, Vilar E From premalignant biology to precision interception: connecting the dots with a curated collection of invited articles. Cancer Prev Res (Phila) 16(7):365-68, 2023. PMID: 37403656.
- Golemis EA, Scheet P, Beck TN, Scolnick E, Hunter DJ, Hawk E, et al Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32(13-14):868-902, 2018. PMID: 29945886.
- Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, et al Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev 36(2):199-213, 2017. PMID: 28730545.
- Maresso KC, Hawk E Cancer prevention recommendations: impact of adherence. Semin Oncol Nurs 32(3):306-13, 2016. PMID: 27539284.
- Umar A, Steele VE, Menter DG, Hawk ET Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 43(1):65-77, 2016. PMID: 26970125.
- Patterson SL, Maresso KC, Hawk E Cancer chemoprevention, successes and failures. Clin Chem 59(1):94-101, 2013. PMID: 23150056.
- Wu X, Patterson S, Hawk E Chemoprevention-history and general principles. Best Pract Res Clin Gastroenterol 25(4-5):445-59, 2011. PMID: 22122762.
- Lippman SM, Hawk ET Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 69(13):5269-84, 2009. PMID: 19491253.
- Hawk E, Viner JL What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment. Semin Oncol 33(6 Suppl 11):S6-S9, 2006. PMID: 17178278.
- Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Hawk ET, et al Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 2006. PMID: 16778094.
- Jankowski JA, Hawk ET A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 3(2):101-11, 2006. PMID: 16456576.
- Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM Statins and cancer prevention. Nat Rev Cancer 5(12):930-42, 2005. PMID: 16341084.
- Hawk ET, Umar A, Richmond E, Viner JL Prevention and therapy of colorectal cancer. Med Clin North Am 89(1):85-110, viii, 2005. PMID: 15527810.
- Hawk ET, Levin B Colorectal cancer prevention. J Clin Oncol 23(2):378-91, 2005. PMID: 15637400.
- Hawk ET, Umar A, Lubet RA, Kopelovich L, Viner JL Can animal models help us select specific compounds for cancer prevention trials?. Recent Results Cancer Res 166:71-87, 2005. PMID: 15648184.
- Lao CD, Backoff P, Shotland LI, McCarty D, Eaton T, Hawk ET, et al Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 13(7):1250-2, 2004. PMID: 15247138.
- Hawk ET, Umar A, Viner JL Colorectal cancer chemoprevention--an overview of the science. Gastroenterology 126(5):1423-47, 2004. PMID: 15131803.
- Umar A, Risinger JI, Hawk ET, Barrett JC Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer 4(2):153-8, 2004. PMID: 14964310.
- Anderson WF, Umar A, Hawk ET Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother 4(12):2193-204, 2003. PMID: 14640918.
- Umar A, Viner JL, Anderson WF, Hawk ET Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 26(4):S48-57, 2003. PMID: 12902856.
- Steele VE, Hawk ET, Viner JL, Lubet RA Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523-524:137-44, 2003. PMID: 12628511.
- Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, et al Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus 16(3):177-86, 2003. PMID: 14641306.
- Hawk ET, Viner J, Richmond E, Umar A Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Cancer Chemother Biol Response Modif 21:759-89, 2003. PMID: 15338773.
- Viner JL, Umar A, Hawk ET Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am 31(4):971-99, 2002. PMID: 12489273.
- Hawk ET, Limburg PJ, Viner JL Epidemiology and prevention of colorectal cancer. Surg Clin North Am 82(5):905-41, 2002. PMID: 12507200.
- Umar A, Viner JL, Richmond E, Anderson WF, Hawk ET Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 7(1):2-26, 2002. PMID: 11942045.
- Anderson WF, Umar A, Viner JL, Hawk ET The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 8(12):1035-62, 2002. PMID: 11945150.
- Umar A, Viner JL, Hawk ET The future of colon cancer prevention. Ann N Y Acad Sci 952:88-108, 2001. PMID: 11795446.
- Anderson WF, Hawk E, Berg CD Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol 28(1):106-20, 2001. PMID: 11254870.
- Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ 154:13-26, 2001. PMID: 11220652.
- Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 9(9):2121-38, 2000. PMID: 11060797.
- Hawk ET, Lippman SM Primary cancer prevention trials. Hematol Oncol Clin North Am 14(4):809-30, 2000. PMID: 10949775.
- Hawk E, Breslow RA, Graubard BI Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 9(5):523-7, 2000. PMID: 10815699.
- Hawk E, Viner JL, Lawrence JA Biomarkers as surrogates for cancer development. Curr Oncol Rep 2(3):242-50, 2000. PMID: 11122849.
- Heath EI, Limburg PJ, Hawk ET, Forastiere AA Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Williston Park) 14(4):507-14; discussion 518-20, 522-3, 2000. PMID: 10826312.
- Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Hawk ET, et al Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 9(2):127-37, 2000. PMID: 10698472.
- Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Hawk ET, et al Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130(2 Suppl):467S-471S, 2000. PMID: 10721931.
- van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Hawk E, et al Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 6(1):78-89, 2000. PMID: 10656435.
- Hawk E, Lubet R, Limburg P Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86(11 Suppl):2551-63, 1999. PMID: 10630181.
- McCaskill-Stevens W, Hawk ET, Flynn PJ, Lippman SM National Cancer Institute--supported cancer chemoprevention research: coming of age. J Clin Oncol 17(11 Suppl):53-62, 1999. PMID: 10630263.
- Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 8(5):467-83, 1999. PMID: 10350444.
- Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Hawk ET, et al Progress in cancer chemoprevention. Ann N Y Acad Sci 889:1-13, 1999. PMID: 10668477.
- Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Hawk ET, et al Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 7(1):65-78, 1998. PMID: 9456245.
- Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, et al Progress in clinical chemoprevention. Semin Oncol 24(2):241-52, 1997. PMID: 9129692.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk ET, Steele VE, et al Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res 396:159-83, 1997. PMID: 9108597.
- Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Nayfield SG, Perloff M, et al Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park) 10(10):1471-84; discussion 1484-8, 1996. PMID: 8905841.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, et al Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl 59(23 Suppl):1-9, 1995. PMID: 8747372.
- Hawk E An Opportunity for Developing Cancer Prevention Leadership in Mexico. J Cancer Educ None(None):None. PMID: None.
- Hawk E An advantageous opportunity for developing cancer prevention leadership in Mexico: Recruiting instructors for a new curriculum in cancer prevention. Pedagogy Health Promot None(None):None. PMID: None.
Editorials
- Hawk E, Martch SL. Recent American college of physicians guidance statement for screening average-risk, asymptomatic adults for colorectal cancer. Cancer Prev Res (Phila) 17(1):1-6, 2024. PMID: 38173395.
- Cohen L, Hawk E. It doesn't need to take 25 years: emphasizing cancer prevention and control in President Biden's Cancer Moonshot. JCO Oncol Pract 19(10):831-34, 2023. PMID: 37672725.
- Agbafe V, Berlin NL, Butler CE, Hawk E, Offodile Ii AC. Prescriptions for mitigating climate change-related externalities in cancer care: A surgeon's perspective. J. Clin. Oncol 40(18):1976-1979, 2022. PMID: 35333584.
- Hawk E, Maresso KC. Aspirin use and cancer prevention: long-term data needed on benefits and risks. The ASCO Post None(None):None, 2019. PMID: None.
- Hawk E, Maresso KC, Brown P. NSAIDs to prevent breast cancer recurrence? An unanswered question. J Natl Cancer Inst 110(9):927-28, 2018. PMID: 29554350.
- Mahon SM, Hawk E. Introduction. Semin Oncol Nurs 32(3):185-6, 2016. PMID: 27539274.
- Vilar E, Maresso KC, Hawk ET. Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol 2(6):770-771, 2016. PMID: 26939883.
- Brenner DE, Hawk E. Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila) 6(2):71-3, 2013. PMID: 23333813.
- Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, et al. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev 17(11):2903-5, 2008. PMID: 18990728.
- Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, et al. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila) 1(6):393-5, 2008. PMID: 19138984.
- Hawk E, Viner JL. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev 16(2):185-7, 2007. PMID: 17301246.
- Hawk E, Viner JL. Statins and cancer-beyond the "one drug-one disease" model. N Engl J Med 352(21):2238-9, 2005. PMID: 15917390.
- Hawk E, Viner JL. The critical role of risk-benefit assessments in cancer prevention. Cancer Epidemiol Biomarkers Prev 14(2):297-8, 2005. PMID: 15734949.
- Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC. Counterpoint: because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12(7):593-6, 2003. PMID: 12869396.
- Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer--a player that's defining the rules. J Natl Cancer Inst 94(8):545-6, 2002. PMID: 11959883.
- Hawk ET, Viner JL. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med 134(2):158-60, 2001. PMID: 11177320.
- Hawk E. Patient needs, physician opportunities, and reimbursement align...Can our clinical practices do similarly?. ASCO Daily News None(None):None. PMID: None.
Abstracts
- Kwan S, Gonzales KA, Jamal MA, Stevenson HL, Tan L, Hawk ET. Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. Gut Microbes 16(1):None, 2024. PMID: 39239875.
- Abu-Sbeih H, Ali F, Qiao W, Lum P, Shafi M, Hawk E, et al. Risk of colonic adenoma in patients with non–colorectal cancers. J Clin Oncol 37(15 suppl):e13070, 2019. PMID: None.
- Shalaby AS, Botrus G, Kaseb AO, Li D, Abdel-Wahab R, Hawk E, et al. The Protective Effect of physical activity on Risk of Hepatocellular Carcinoma in USA. J Clin Oncol 34(15 Suppl):e15642, 2016. PMID: None.
- Peleg S, Shukla V, Mazumdar A, Curley SA, Hawk E, Brown PH, et al. High Dose Vitamin D Suppresses Growth of HCC Cell Lines and Reduces Hepatocyte Proliferation in β2–spectrin+/- Mice. Hepatology 54(4 Suppl):1304A, 2011. PMID: None.
- Lutz TA, Lopez R, Burke CA, Lynch P, Hawk E, Griebel D, et al. Is hearing loss an extracolonic manifestation of FAP?. Am J Gastroenterol 101(Suppl 554):1456, 2006. PMID: None.
- Burke CA, Lynch PM, Phillips R, Hawk E, Church J, Hasson H, et al. Considerations for maximizing randomization in chemoprevention trials in FAP. Familial Cancer 4(None):76-77, 2005. PMID: None.
- Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayes GD. Colonoscopy in a phase I safety trial of celecoxib in children with FAP. Familial Cancer 4:57, 2005. PMID: None.
- Burke C, Hawk E, Eagle C, Wolog M, Church J, Hasson H, et al. Design and primary safety outcome in a phase I trial of celecoxib in children with FAP. Familial Cancer 4(None):77-8 (A P29), 2005. PMID: None.
- Peterson SK, Askins MA, Watts BG, Burke CA, Hasson H, Hawk E, et al. Family resiliency and functioning among families with APC-positive children. Familial Cancer 4(1 Suppl):49-50, 2005. PMID: None.
- Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, et al. Efficacy and safety in a phase I safety trial of celecoxib in children with FAP. AGA None(None):None, 2005. PMID: None.
- Peterson SK, Lynch PM, Burke C, Church J, Hasson H, Hawk E. Psychosocial evaluation of children and parents involved in a phase I study of celecoxib in children with FAP. CGA None(None):None, 2004. PMID: None.
- Lynch PM, Steinbach G, Hittelman W, Terry N, Frazier M, Hawk E, et al. A phase II chemoprevention trial in HNPCC utilizing a selective cyclooxygenase 2 inhibitor: protocol description and progress to date. J Gastroenterol Hepatol 14(8):A59, 1999. PMID: None.
- Steinbach G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordon G. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP). Am J Gastroenterol 94(9):440, 1999. PMID: None.
- Peleg S, Shetty K, Shukla V, Amdur R, Patel K, Hawk E, et al. Vitamin D as a Chemopreventive Agent for Hepatocellular Carcinoma (HCC). AASLD None(None):None. PMID: None.
- Yao Z, Jogunoori W, Peleg S, Amdur R, Patel K, Hawk E, et al. Restoration of Key TGF-β signaling Proteins by Vitamin D in Cirrhotic Human Livers with and without Hepatocellular Carcinoma (HCC). AASLD None(None):None. PMID: None.
Book Chapters
- Maresso, KC, Basen-Engquist, KM, Hawk, E. Cancer epidemiology, prevention, and survivorship. In: Perioperative Care of the Cancer Patient, 3-14, 2023.
- Bevers T, El-Serag H, Hanash S, Thrift AP, Tsai K, Hawk E, et al. Screening and early detection. In: Abeloff's Clinical Oncology. 6th. Elsevier, 375-98.e7, 2019.
- Basen-Engquist K, Brown P, Coletta AM, Savage M, Maresso KC, Hawk E. Lifestyle and cancer prevention. In: Abeloff's Clinical Oncology. 6th. Elsevier, 337-74, 2019.
- Menter, DG, Davis, JS, Tucker, SC, Hawk, E, Crissman, JD, Sood, AK, et al. Platelets: "First responders" in cancer progression and metastasis. In: Platelets in Thromb. and Non-Thromb. Disord.: Pathophysiol., Pharmacol. and Ther.: an Update. Springer, 1111-32, 2017.
- Colbert Maresso K, Hawk E. Designing the chemoprevention trials of tomorrow: applying lessons learned from past definitive trials. In: Cancer prevention: dietary factors and pharmacology. None. Humana Press, 265-84, 2013.
- Bevers TB, Brown PH, Maresso KC, Hawk ET. Cancer prevention, screening, and early detection. In: Abeloff's Clinical Oncology. 5th. Elsevier, 322-59, 2013.
- Hawk ET, Patterson SL, Mishra L, Patel KK. Colorectal cancer prevention and aging. In: Cancer and Aging Handbook: Research and Practice. None. John Wiley & Sons, 85-96, 2012.
- Viner JL, Hawk E, Lippman S. Cancer chemoprevention. In: Cancer epidemiology and prevention. 3rd. Oxford Univ. Press, 1318-40, 2006.
- Hawk E. COX-2 in cancer. In: Targeted cancer therapies, an odyssey: tromsø symposium 2003. None. Tromso Univ. Press, 92-5, 2003.
- Hawk E, Sigman CC, Kelloff G. Prevention of gastrointestinal cancers. In: Gastrointestinal oncology. None. Saunders, 205-14, 2003.
- Anderson WF, Umar A, Viner JL, Hawk ET. Potential role of NSAIDs and COX-2 blockade in cancer therapy. In: COX-2 blockade in cancer prevention and therapy. None. Humana, 313-40, 2003.
- Hawk ET, Viner JL, Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2 selective inhibitors in clinical cancer prevention trials. In: COX-2: a new target for cancer prevention and treatment. Karger, 210-42, 2003.
- Hawk ET, Viner JL, Limburg PJ. Epidemiology and prevention of colorectal cancer. In: Gastrointestinal oncology. None. Oxford Univ. Press, 593-634, 2003.
- Viner J, Richmond E, Hawk E, Lawrence J. Chemoprevention. In: The cancer handbook. None. Nature, 1417-38, 2002.
- Watson AJM, Hawk E, DuBois RN. Chemoprevention of colorectal cancer. In: Gastrointestinal oncology. 1. Saunders, 421-428, 2002.
- Schatzkin A, Goldstein A, Hawk E. Chemo-and dietary prevention of familial cancer: from theory to practice. In: Familial cancer and prevention: molecular epidemiology: a new strategy. None. Wiley & Sons, 295-301, 1999.
Books (edited and written)
- Hawk E. Holland-Frei Cancer Medicine, 10th edition. Ed(s) 10th. Wiley-Blackwell, 2023.
- Jankowski J, Hawk E. Handbook of gastrointestinal cancer. Ed(s) None. John Wiley & Sons, 2012.
- Kelloff GJ, Hawk ET, Sigman CC. Cancer chemoprevention. Ed(s) None. Humana Press, 2005.
- Kelloff GJ, Hawk ET, Sigman CC. Cancer chemoprevention. Ed(s) None. Humana Press, 2004.
Letters to the Editor
- Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, et al. Assessment of compliance with Texas legislation banning indoor UV tanning by minors. JAMA Dermatol 153: 228-229, 2017.
- Hawk E, Prindiville S, Kelloff G. NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology 110: 654-5, 1996.
Grant & Contract Support
| Title: | Project 3: Non-Invasive Assessment of Liver Fibrosis Stage and Progression in Obesity and Diabetes: A Hispanic Population Study |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Core Infrastructure Support |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Cancer Center Support Grant |
| Funding Source: | NIH/NCI |
| Role: | Member, CCSG Senior Leadership/Associate Director Population Sciences; Director Community Outreach and Engagement; Co-Leader GI Program |
| Title: | Advances in our understanding of the mechanisms of obesity and radiation in carcinogenesis, and personalized cancer etiology |
| Funding Source: | John Templeton Foundation |
| Role: | Co-I |
| Title: | Be Well Communities(TM): A Model for Cancer Prevention & Control in Underserved Communities |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| Title: | Expansion of cervical cancer prevention services to medically underserved populations through patient outreach, navigation & provider training/telementoring |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Program Director |
| Title: | INCan Collaborative Development of a Curriculum in Cancer Prevention and Control for the Institute Nacional de Cancerologia in Mexico |
| Funding Source: | CRDF Global |
| Role: | PI |
| Title: | Aspirin-PC for Chemoprevention of Colorectal Cancer |
| Funding Source: | PLX Pharma |
| Role: | Co-I |
| Title: | Administrative Supplements for NCI-designated Cancer Centers to Support Population Health Assessment in Cancer Center Catchment Areas |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Genome-Wide Association Study in Hepatocellular Carcinoma (GWAS Study) |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator (Year 5) |
| Title: | Improving Cervical Cancer Screening and Prevention in the Lower Rio Grande Valley Through Public Outreach, Patient Navigation, and Telementoring |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Program Director |
| Title: | Discovering New Targets for Chemoprevention in FAP |
| Funding Source: | NIH/NCI |
| Role: | Significant Contributor |
| Title: | A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X/Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients with FAP and Attenuated FAP |
| Funding Source: | Cancer Prevention Pharmaceuticals |
| Role: | Co-PI |
| Title: | Aspirin-PC for Chemoprevention of Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Consult |
| Title: | Use of a FIT-Flu Intervention to Increase Colorectal Cancer Screening Rates in the Houston Metropolitan Area |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Program Director |
| Title: | Chemoprevention of Colon Cancer by Targeting APC-deficient Cells for Apoptosis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | Enhancing Minority Participants in Clinical Trials (EMPaCT): Phase II |
| Funding Source: | NIH/NIMH |
| Role: | Co-PI |
| Title: | Role of microRNA in Colorectal Cancer Clinical Outcome Prediction: a Genome-wide Analysis |
| Funding Source: | The University of Texas M.D. Anderson Cancer Center |
| Role: | Co-I |
| Title: | Chemoprevention of Colon Cancer by Targeting APC-deficient Cells for Apoptosis |
| Funding Source: | The University of Texas M.D. Anderson Cancer Center |
| Role: | Co-I |
| Title: | Enhancing Minority Participants in Clinical Trials (EMPaCT) |
| Funding Source: | NIH/NCI |
| Role: | Co-Director |
| Title: | Cellular and Molecular Mechanisms of Gastrointestinal Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | MicroRNA and clinical outcome of esophageal cancer: a genome-wide analysis of germline genetic variations and somatic molecular alterations |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Risk Factors of Hepatocellular Carcinoma in the USA |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Comparative Effectiveness Research Project |
| Funding Source: | AHRQ |
| Role: | PI |
| Title: | Therapeutic Prevention for Colon Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Title: | Development of PC-conjugated Aspirin for Colon Cancer Prevention |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
| Title: | HPV vaccine hesitancy and uptake within The University of Texas System - A catalyst for population-level advances |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| Title: | Cannabis use among cancer patients and survivors: access, use patterns, knowledge, perceived risks and benefits; and interactions with healthcare providers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| Title: | The Role of Methyl Donors in Cancer Risk |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Integrative Analysis of Sequencing Data for Adenoma Development |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Molecular Characterization of Aspirin for Colorectal Cancer Treatment and Prevention |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Title: | Multi-Ethnic Cancer Survivorship Cohort |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | SPORE in Liver Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator Project 3 |
| Title: | Gut microbiome: integrating risk pathways in obesity and colorectal neoplasia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Esophagus SPORE: Biology of Barrett's Esophagus and Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Creation of the MD Anderson Cancer Patient Cohort (MDACPC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | MD Anderson SPORE in Hepatocellular Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | A web-based Computational Tool for Prediction of Colorectal Cancer Outcomes |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Implementation of CT Colonography in the Harris County Hospital District for the Diagnostic Evaluation of Patients with Positive FOBT/FIT Test Results |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Significant Contributor |
| Title: | Project ACCESS: Increasing Access to Cervical Cancer Screening & Treatment Services in Texas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
Patient Reviews
CV information above last modified November 19, 2024